EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Long‐term safety and tolerability of hyaluronidase‐facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: Results from the ADVANCE‐CIDP 3 trial

Robert D M Hadden iD, Henning Andersen iD, Vera Bril iD, Ivana Basta iD, Konrad Rejdak iD, Kim Duff iD, Erin Greco, Shabbir Hasan, Colin Anderson-Smits, Hakan Ay iD

Journal of the Peripheral Nervous System · 2024-12 · 29 (4) · 441-452

DOI: 10.1111/jns.12672 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of the Peripheral Nervous System, online erschienen am 11.11.2024. Verfasst von Robert D M Hadden und 9 weiteren Autor:innen. Beteiligte Einrichtung: Neurology Department, King's College Hospital, London, UK. Hauptthemen laut MEDLINE: Hyaluronoglucosaminidase, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Takeda Development Center Americas, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Hyaluronidase‐facilitated subcutaneous immunoglobulin (fSCIG) consists of subcutaneous human immunoglobulin G (IgG) 10% with recombinant human hyaluronidase (rHuPH20) and can be administered at the same dose and interval as intravenous IgG (IVIG). fSCIG recently received US approval as maintenance therapy for adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and European approval for adults and children with CIDP after stabilization with IVIG.

Methods

ADVANCE‐CIDP 3 (NCT02955355) was an open‐label long‐term extension of the Phase 3 double‐blind randomized placebo‐controlled ADVANCE‐CIDP 1 study (NCT02549170) that examined fSCIG safety and efficacy as maintenance CIDP therapy. Primary outcomes were safety, tolerability, and immunogenicity. Efficacy was an exploratory outcome.

Results

The study provided 220 patient‐years of follow‐up data from 85 patients. Median (range) exposure was 33 (0–77) months. Patients received fSCIG every 4 weeks (88.2%) or every 3 weeks (11.8%). Median (range) 4‐weekly IgG dose equivalent was 64.0 (28.0–200.0) g. Mean (standard deviation) infusion duration was 135.5 (62.8) minutes. Most adverse events (AEs) were mild or moderate and self‐limiting. Of the 1406 AEs, only 48 were severe and 30 were serious. fSCIG‐related AEs ( n = 798) included infusion site reactions such as pain, redness, and pruritus. Three infusions (0.1%) were reduced in rate, interrupted, or stopped due to intolerability. Relapse occurred in 10 of 77 patients (13.0%); annual relapse rate was 4.5%. An anti‐rHuPH20 antibody titer ≥1:160 was detected in 14 of 84 patients (16.7%); patients who tested positive (≥1:160) had similar relapse rates versus those who tested negative (16.7% vs. 12.3%, respectively).

Interpretation

ADVANCE‐CIDP 3 demonstrated favorable fSCIG long‐term safety and tolerability consistent with its established safety profile, and a low relapse rate, supporting use as maintenance CIDP treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HyaluronoglucosaminidasePolyradiculoneuropathy, Chronic Inflammatory DemyelinatingHumansMaleFemaleMiddle AgedAdultAgedDouble-Blind MethodImmunoglobulin GYoung AdultAged, 80 and overAdolescentTreatment OutcomeInjections, SubcutaneousImmunologic FactorsFollow-Up Studies

Stichwörter der Autor:innen

ADVANCE‐CIDP 3chronic inflammatory demyelinating polyradiculoneuropathyhyaluronidase‐facilitated subcutaneous immunoglobulin 10%long‐term safety and tolerabilityopen‐label extension study

Substanzen

HyaluronoglucosaminidaseImmunoglobulin GImmunologic Factors

Autor:innen und Institutionen

  • Neurology Department, King's College Hospital, London, UK.
  • Department of Basic & Clinical Neuroscience, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
  • Department of Neurology, Aarhus University Hospital, Aarhus, Denmark.
  • The Ellen & Martin Prosserman Centre for Neuromuscular Diseases, University Health Network, University of Toronto, Toronto, Ontario, Canada.
  • Faculty of Medicine, Neurology Clinic, University Clinical Center of Serbia, University of Belgrade, Belgrade, Serbia.
  • Department of Neurology, Medical University of Lublin, Lublin, Poland.

ORCID-Profile: Robert D M Hadden, Henning Andersen, Vera Bril, Ivana Basta, Konrad Rejdak, Kim Duff, Hakan Ay

Förderung

  • Takeda Development Center Americas, Inc.

Zitieren

APA

Hadden, R. D. M., Andersen, H., Bril, V., Basta, I., Rejdak, K., Duff, K., Greco, E., Hasan, S., Anderson-Smits, C., & Ay, H. (2024). Long‐term safety and tolerability of hyaluronidase‐facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: Results from the ADVANCE‐CIDP 3 trial. Journal of the Peripheral Nervous System, 29(4), 441-452. https://doi.org/10.1111/jns.12672

Vancouver

Hadden RDM, Andersen H, Bril V, Basta I, Rejdak K, Duff K, et al. Long‐term safety and tolerability of hyaluronidase‐facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: Results from the ADVANCE‐CIDP 3 trial. Journal of the Peripheral Nervous System. 2024;29(4):441-452. doi:10.1111/jns.12672

BibTeX
@article{Hadden2024,
  author = {Hadden, Robert D M and Andersen, Henning and Bril, Vera and Basta, Ivana and Rejdak, Konrad and Duff, Kim and Greco, Erin and Hasan, Shabbir and Anderson-Smits, Colin and Ay, Hakan},
  title = {Long‐term safety and tolerability of hyaluronidase‐facilitated subcutaneous immunoglobulin 10% as maintenance therapy for chronic inflammatory demyelinating polyradiculoneuropathy: Results from the ADVANCE‐CIDP 3 trial},
  journal = {Journal of the Peripheral Nervous System},
  year = {2024},
  volume = {29},
  number = {4},
  pages = {441--452},
  doi = {10.1111/jns.12672}
}
Kostenlos starten →